Pterostilbene: a Potential Therapeutic Agent for Fibrotic Diseases

Overview

Journal Inflammopharmacology

Specialty Pharmacology

Date 2024 Mar 1

PMID 38429613

Authors

Wenhong Wang

Ke Li

Dandan Bai

Jiabin Wu

Weihua Xiao

Affiliations

Soon will be listed here.

Abstract

Fibrosis is a prevailing pathology in chronic diseases and accounts for 45% of deaths in developed countries. This condition is primarily identified by the transformation of fibroblasts into myofibroblasts and the overproduction of extracellular matrix (ECM) by myofibroblasts. Pterostilbene (PTS) is a natural analogue of resveratrol and is most commonly found in blueberries. Research has shown that PTS exerts a wide range of pharmacological effects, such as antioxidant, anti-inflammatory, and anticancer effects. As a result, PTS has the potential to prevent and cure numerous diseases. Emerging evidence has indicated that PTS can alleviate myocardial fibrosis, renal fibrosis, pulmonary fibrosis, hepatic fibrosis, and colon fibrosis via the inhibition of inflammation, oxidative stress, and fibrogenesis effects in vivo and in vitro, and the potential mechanisms are linked to various pathways, including transforming growth factor-β1 (TGF-β1)/small mother against decapentaplegic proteins (Smads) signalling, the reactive oxygen species (ROS)-driven Pitx2c/mir-15b pathway, nuclear factor kappa B (NF-κB) signalling, Kelch-like epichlorohydrin-associated protein-1 (Keap-1)/NF-E2-related factor-2 (Nrf2) cascade, the NLR family pyridine structure domain 3 (NLRP3) pathway, the Janus kinase-2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) pathway, and the Src/STAT3 pathway. In this review, we comprehensively summarize the antifibrotic effects of PTS both in vivo and in vitro and the pharmacological mechanisms, pharmacokinetics, and toxicology of PTS and provide insights into and strategies for exploring promising agents for the treatment of fibrosis.

References

Afratis N, Klepfish M, Karamanos N, Sagi I . The apparent competitive action of ECM proteases and cross-linking enzymes during fibrosis: Applications to drug discovery. Adv Drug Deliv Rev. 2018; 129:4-15. DOI: 10.1016/j.addr.2018.03.004. View

Aly S, El-Kamel A, Sheta E, El-Habashy S . Chondroitin/Lactoferrin-dual functionalized pterostilbene-solid lipid nanoparticles as targeted breast cancer therapy. Int J Pharm. 2023; 642:123163. DOI: 10.1016/j.ijpharm.2023.123163. View

Appenroth D, Lupp A, Kriegsmann J, Sawall S, Splinther J, Sommer M . Temporary warm ischaemia, 5/6 nephrectomy and single uranyl nitrate administration--comparison of three models intended to cause renal fibrosis in rats. Exp Toxicol Pathol. 2001; 53(4):316-24. DOI: 10.1078/0940-2993-00197. View

Aydin M, Akcali K . Liver fibrosis. Turk J Gastroenterol. 2018; 29(1):14-21. PMC: 6322608. DOI: 10.5152/tjg.2018.17330. View

Azzolini M, La Spina M, Mattarei A, Paradisi C, Zoratti M, Biasutto L . Pharmacokinetics and tissue distribution of pterostilbene in the rat. Mol Nutr Food Res. 2014; 58(11):2122-32. DOI: 10.1002/mnfr.201400244. View

Azzolini M, Mattarei A, La Spina M, Fanin M, Chiodarelli G, Romio M . New natural amino acid-bearing prodrugs boost pterostilbene's oral pharmacokinetic and distribution profile. Eur J Pharm Biopharm. 2017; 115:149-158. DOI: 10.1016/j.ejpb.2017.02.017. View

Bae M, Park Y, Lee J . Food components with antifibrotic activity and implications in prevention of liver disease. J Nutr Biochem. 2017; 55:1-11. PMC: 5936673. DOI: 10.1016/j.jnutbio.2017.11.003. View

Banerjee I, Yekkala K, Borg T, Baudino T . Dynamic interactions between myocytes, fibroblasts, and extracellular matrix. Ann N Y Acad Sci. 2006; 1080:76-84. DOI: 10.1196/annals.1380.007. View

Bin Jardan Y, Ahad A, Raish M, Al-Mohizea A, Al-Jenoobi F . Microwave-Assisted Formation of Ternary Inclusion Complex of Pterostilbene. Pharmaceuticals (Basel). 2023; 16(12). PMC: 10747933. DOI: 10.3390/ph16121641. View

10.

Cai X, Du X, Zhu G, Shi X, Chen Q . Fabrication of carboxymethyl starch/xanthan gum combinations Pickering emulsion for protection and sustained release of pterostilbene. Int J Biol Macromol. 2023; 248:125963. DOI: 10.1016/j.ijbiomac.2023.125963. View

11.

Canatar I, Zenger O, Ozdas S, Baydemir Pesint G . Pterostilbene loaded poly(vinyl alcohol)-gelatin cryogels as potential bioactive wound dressing material. J Biomed Mater Res B Appl Biomater. 2023; 111(6):1259-1270. DOI: 10.1002/jbm.b.35230. View

12.

Catenacci L, Vicatos A, Sorrenti M, Bonferoni M, Caira M . Native Cyclodextrins as Complexation Agents for Pterostilbene: Complex Preparation and Characterization in Solution and in the Solid State. Pharmaceutics. 2022; 14(1). PMC: 8777607. DOI: 10.3390/pharmaceutics14010008. View

13.

Catenacci L, Vicatos A, Sorrenti M, Edmonds-Smith C, Bonferoni M, Caira M . Complexation between the Antioxidant Pterostilbene and Derivatized Cyclodextrins in the Solid State and in Aqueous Solution. Pharmaceuticals (Basel). 2023; 16(2). PMC: 9966925. DOI: 10.3390/ph16020247. View

14.

Chanda D, Otoupalova E, Smith S, Volckaert T, De Langhe S, Thannickal V . Developmental pathways in the pathogenesis of lung fibrosis. Mol Aspects Med. 2018; 65:56-69. PMC: 6374163. DOI: 10.1016/j.mam.2018.08.004. View

15.

Coresh J, Selvin E, Stevens L, Manzi J, Kusek J, Eggers P . Prevalence of chronic kidney disease in the United States. JAMA. 2007; 298(17):2038-47. DOI: 10.1001/jama.298.17.2038. View

16.

Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre J . Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005; 54(2):237-41. PMC: 1774826. DOI: 10.1136/gut.2004.045294. View

17.

Wang X, Xie W, Cai L, Han C, Kuang H, Shao Y . Microencapsulated Encoding Lactoferricin-Lactoferrampin Targeted Intestine against Infection. Nutrients. 2023; 15(24). PMC: 10745908. DOI: 10.3390/nu15245141. View

18.

DAlessio S, Ungaro F, Noviello D, Lovisa S, Peyrin-Biroulet L, Danese S . Revisiting fibrosis in inflammatory bowel disease: the gut thickens. Nat Rev Gastroenterol Hepatol. 2021; 19(3):169-184. DOI: 10.1038/s41575-021-00543-0. View

19.

Dellinger R, Garcia A, Meyskens Jr F . Differences in the glucuronidation of resveratrol and pterostilbene: altered enzyme specificity and potential gender differences. Drug Metab Pharmacokinet. 2013; 29(2):112-9. PMC: 4487664. DOI: 10.2133/dmpk.dmpk-13-rg-012. View

20.

Ding R, Huang G, Zhang Y, Sun H, Liu Y, Xu Z . Pterostilbene Ameliorates Renal Damage in Diabetic Rats by Suppressing Hyperglycemia with Inhibition of Inflammatory and Fibrotic Responses. Biomed Environ Sci. 2022; 34(12):1015-1019. DOI: 10.3967/bes2021.137. View